Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings
Abstract
Oncotype DX (ODx) is a 12-gene assay assessing the recurrence risk (high, intermediate, and low) of ductal carcinoma in situ (pre-invasive breast cancer), which guides clinicians regarding prescription of radiotherapy. However, ODx is expensive, time-consuming, and tissue-destructive. In addition, the actual prognostic meaning for the intermediate ODx risk category remains unclear.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 17, 2019
- Source ID
- 10.1186/s13058-019-1200-6
Entities
People
- Anant Madabhushi
- Hannah Gilmore
- Haojia Li
- Jon Whitney
- Kaustav Bera
- Mangesh A. Thorat
- Sunil Badve
Organizations
- National Cancer Institute
- United States Department of Veterans Affairs